Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset OTC Deficiency



Status:Recruiting
Conditions:Metabolic
Therapuetic Areas:Pharmacology / Toxicology
Healthy:No
Age Range:18 - Any
Updated:4/4/2019
Start Date:January 2017
End Date:December 2020
Contact:Patients Contact: Patient Advocacy
Email:patientadvocacy@ultragenyx.com
Phone:1-415-483-8800

Use our guide to learn which trials are right for you!

A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults With Late-Onset OTC Deficiency

A Phase 1/2, open-label dose-finding safety study of single ascending doses of DTX301 in
adults with late-onset OTC Deficiency

This is a Phase 1/2, open-label, single arm, multicenter, safety and dose finding study of
DTX301 in adults with late-onset OTC deficiency. The primary objective of the study is to
establish a dose of DTX301 that has a clinically meaningful increase in the rate of
ureagenesis. Eligible subjects will receive a single IV infusion of DTX301. Dose escalation
will be conducted according to a model that uses the collected data to predict the safety
profile of the dose in order to determine the optimal biological dose (OBD). The decision to
proceed to the next dose cohort will be made after the data monitoring committee (DMC) has
evaluated the safety data for all subjects in a dosing cohort.

Subjects will be followed for 52 weeks after dosing. After completion of this study, subjects
will be asked to enroll in a 4-year extension study to evaluate the long term (a total of 5
years) safety and efficacy of DTX301.

This study was previously posted by Dimension Therapeutics, which has been acquired by
Ultragenyx.

Inclusion Criteria:

1. Males and females ≥18 years of age with documented diagnosis of late onset (defined as
first manifestation of signs and symptoms at ≥1 month of age) OTC deficiency,
confirmed via enzymatic, biochemical, or molecular testing

2. Documented history of ≥1 symptomatic hyperammonemia event with ammonia ≥100 µmol/L.

3. Subject's OTC deficiency is stable as evidenced by either a) no clinical symptoms of
hyperammonemia OR b) an ammonia level <100 µmol/L within the 4 week period preceding
the Screening visit.

4. On stable dose of ammonia scavenger therapy for ≥4 weeks.

5. Males and all females of childbearing potential must be willing to use effective
contraception at the time of administration of gene transfer and for the 52 weeks
following administration of DTX301

Exclusion Criteria:

1. Screening or Baseline (Day 0) ammonia level ≥100 µmol/L or signs and symptoms
indicative of hyperammonemia during the 4-week period preceding Day 0

2. Liver transplant, including hepatocyte cell therapy/transplant.

3. History of liver disease

4. Serum creatinine >2.0 mg/dL.

5. Participation in another investigational medicine study (including another gene
transfer trial) within 3 months of Screening

6. History of a malignancy for which the subject has received treatment in the past 2
years except for prostate cancer treated with watchful waiting or surgically removed
non-melanoma skin cancer.
We found this trial at
8
sites
300 Longwood Ave
Boston, Massachusetts 02115
(617) 355-6000
Phone: 617-355-6000
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
?
mi
from
Boston, MA
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Phone: 503-494-7608
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
13123 E 16th Ave
Aurora, Colorado 80045
(720) 777-1234
Phone: 303-724-2334
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
2888 Shaganappi Trail Northwest
Calgary, Alberta T3B 6A8
Phone: (403) 955-7587
?
mi
from
Calgary,
Click here to add this to my saved trials
11100 Euclid Avenue
Cleveland, Ohio 44106
Phone: 216-844-3936
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
757 Westwood Plaza
Los Angeles, California 90095
Phone: 310-267-9592
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1428 Madison Ave
New York, New York 10029
(212) 241-6500
Phone: 212-241-6947
Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai is...
?
mi
from
New York, NY
Click here to add this to my saved trials
San Francisco, California 94143
Phone: 415-476-3572
?
mi
from
San Francisco, CA
Click here to add this to my saved trials